



NSAI

Quality System Approval Certificate

Medical Devices Directive 93/42/EEC

*The National Standards Authority of Ireland as a duly designated
Notified Body, (identification number 0050), for the purposes of the European Communities
(Medical Devices) Regulations (S.I. No. 252 of 1994)*

APPROVES THE QUALITY SYSTEM APPLIED BY

Becton Dickinson and Company

**1 Becton Drive
Franklin Lakes
NJ 07417
USA**

to the Product Family

**Autoinjector Needles (BD™, BD Micro-Fine™, BD Micro-Fine™+, BD
Micro-Fine™ Plus, BD Micro-Fine Ultra™, BD Micro-Fine Ultra™ PRO,
BD Ultra-Fine™, BD Ultra-Fine™ PRO, BD Ultra-Fine™ 2nd Gen, BD
Nano™, BD Viva™, BerliFine® Micro and Accu-Fine® Pen Needles)**

GMDN Code: 44127

*on the basis of examination under the requirements of Directive 93/42/EEC on Medical Devices Annex V.
The use of the NSAI Notified Body identification number 0050 in conjunction with CE Marking of
Conformance for this product family is hereby authorised.*

Registration Number:	252.128
Original Approval:	22 February 1995
Last Amended on:	05 February 2021
Remains valid until:	26 May 2024

Signed:

Approved by:
Dr. Caroline Dore Geraghty
Director, Medical Devices

Approved by:
Dr. Elaine Darcy
European Medical Device Operations Manager

This certificate remains valid on condition that the Approved Quality System is maintained in an adequate and efficacious manner.
Details of the current product range and operational locations included within the scope of this approval can be obtained from NSAI
National Standards Authority of Ireland, 1 Swift Square, Northwood, Santry, Dublin 9, Ireland.



Manufacturer's Declaration

in relation to Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices, in particular with respect to

- the validity of certificates issued under Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) or Council Directive 93/42/EEC on Medical Devices (MDD) (Directive Certificates) *and/or*¹
- the compliance of the devices and us as their manufacturer with the conditions for the continued placing on the market and putting into service

Manufacturer name	Becton, Dickinson and Company
Manufacturer address and contact details	1 Becton Drive Franklin Lakes, New Jersey 07417, USA Heather Reed, VP Global Regulatory Affairs heather.reed@embecta.com
Single Registration Number (SRN) (if available)	US-MF-000019182

Authorised Representative name (if applicable)	BD Medical – Diabetes Care Becton Dickinson France S.A.S.
Authorised Representative address and contact details	11, rue Aristide Bergès, BP 4 38801 Le Pont-de-Claix Cedex, France Laura Deslandes-Azaiez, Regulatory Affairs Manager EU/MEA laura.deslandes-azaiez@embecta.com
Single Registration Number (SRN) (if available)	FR-AR-000011519

¹ The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body.



Notified body name (if applicable)	NSAI X See attached schedule
Notified body number (if applicable)	0050 X See attached schedule
Directive Certificate number(s) to which this confirmation is made (if applicable)	252.128 – BD Pen Needles 252.140 – BD Insulin Syringes X See attached schedule
Original expiry date as indicated on the Directive Certificate prior to the extension of the validity (if applicable)	26 May 2024 (252.128) 25 May 2024 (252.140) X See attached schedule
End date of extended validity/transition period	31 December 2028 X See attached schedule

We, as the manufacturer declare under our sole responsibility:

- for the above listed **Directive Certificate** (or see attached schedule, if multiple certificates) the conditions for the legal extension of validity as required in Article 120.2 of the MDR are met *and/or*²
- the listed **device(s)** in the attached schedule and we as their manufacturer are in compliance with the conditions listed in Article 120.3c of the MDR for continued placing on the market and putting into service,

namely by fulfilling the following conditions:

➤ **Directive Certificate(s)** as listed above or in the attached schedule

- Directive Certificate(s) covering the listed device(s) was/were issued after 25 May 2017, was/were valid on 26 May 2021 and have not been withdrawn afterwards.

Choose applicable statements:

Expired *before* 20 March 2023:

- Before the original date of expiry as indicated on the Directive Certificate(s), we and the notified body have signed written agreement(s) in accordance with Section 4.3, second subparagraph of Annex VII to this Regulation for the conformity assessment(s) in respect of the device(s) covered by the expired certificate(s) or in respect of a device(s) intended to substitute that/those device(s), or

² The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body

- A Competent Authority has granted a derogation from the applicable conformity assessment procedure in accordance with Article 59(1) MDR (may be provided upon request), or
- A Competent Authority has required the manufacturer, in accordance with Article 97(1) MDR, to carry out the applicable conformity assessment procedure (may be provided upon request)

Choose one of the following statements only if a derogation per Article 59(1) or a requirement per Article 97(1) has been granted by a Competent Authority:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

■ Expired/expires after 20 March 2023:

Choose one applicable statement:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

➤ **Upclassified devices**

In case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body:

Choose one applicable statement:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitutes and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.



1 Becton Drive
Franklin Lakes, NJ 07417

bd.com

➤ **Quality Management System (QMS)**

Choose one applicable statement:

- A QMS in accordance with Article 10(9) MDR will be put in place by no later than 26 May 2024.
- A QMS in accordance with Article 10(9) MDR is in place.
- A notified body has issued the attached certificate for the MDR-compliant QMS.

➤ **Device(s) as listed in the attached schedule**

- The device(s) continue to comply with the AIMDD or MDD.
- There are no significant changes in the design and intended purpose.
- The device(s) do not present an unacceptable risk to health or safety of patients, users or other persons, or to other aspects of the protection of public health.

Signed for and on behalf of the manufacturer:

Becton, Dickinson and Company,
BD Medical – Diabetes Care

DATE: 23 Feb 2024

Signature

A handwritten signature in blue ink, appearing to be 'HR', with a long horizontal line extending to the right.

Heather Reed

VP Global Regulatory Affairs

heather.reed@embecta.com



Schedule of Devices

1. Becton Drive
Franklin Lakes, NJ 07417

bd.com

The above Manufacturer's Declaration is valid for the following devices:

Identification of the device(s) ³ (e.g., device name, family/group name, device model or catalogue number)	Directive Certificate number(s) to which this confirmation is made (if applicable)	Original expiry date as indicated on the Directive Certificate (s) prior to the extension of the validity (if applicable)	Notified Body name and number that issued the Directive Certificate (if applicable)	Notified Body name and number where the MDR application was lodged/contract signed (if applicable)	End date of extended validity / transition period	Substitute Device(s) (if applicable)
BD Pen Needles	252.128	26 May 2024	NSAI 0050	NSAI 0050	31 December 2028	N/A
BD Insulin Syringes	252.140	25 May 2024	NSAI 0050	BSI 2797	31 December 2028	N/A

³ for devices with AIMDD/MDD certificate(s) the identification should be as in the certificate, and only if the certificate has a generic scope it should be as defined above)